Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year High at $16.44

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $16.44 and last traded at $16.10, with a volume of 1329817 shares. The stock had previously closed at $13.90.

Analyst Ratings Changes

Several research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. TD Cowen upgraded Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 26th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Monday, May 6th. Finally, JPMorgan Chase & Co. raised their target price on Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a report on Tuesday, March 26th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $20.57.

Stoke Therapeutics Price Performance

The stock has a fifty day moving average price of $11.23 and a two-hundred day moving average price of $7.28. The company has a market cap of $839.13 million, a P/E ratio of -6.68 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts' expectations of $3.70 million. Equities analysts predict that Stoke Therapeutics, Inc. will post -2.31 earnings per share for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, CEO Edward M. Md Kaye sold 11,150 shares of the stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company's stock, valued at $423,035. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 3,600,000 shares of the firm's stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $11.60, for a total value of $41,760,000.00. Following the completion of the sale, the insider now directly owns 10,843,681 shares of the company's stock, valued at $125,786,699.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the firm's stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $68,015.00. Following the completion of the sale, the chief executive officer now directly owns 69,350 shares of the company's stock, valued at $423,035. The disclosure for this sale can be found here. Over the last three months, insiders sold 3,622,741 shares of company stock valued at $41,935,115. 11.30% of the stock is owned by insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently made changes to their positions in STOK. Price T Rowe Associates Inc. MD boosted its stake in Stoke Therapeutics by 5.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company's stock valued at $425,000 after buying an additional 1,642 shares during the period. Bank of New York Mellon Corp boosted its stake in Stoke Therapeutics by 2.8% during the third quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company's stock valued at $423,000 after buying an additional 2,926 shares during the period. BNP Paribas Financial Markets boosted its stake in Stoke Therapeutics by 86.2% during the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company's stock valued at $193,000 after buying an additional 6,636 shares during the period. State Board of Administration of Florida Retirement System bought a new stake in Stoke Therapeutics during the first quarter valued at $141,000. Finally, Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics during the third quarter valued at $43,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.